$180 Million is the total value of venBio Partners LLC's 6 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 33.3% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
Sell | VENTYX BIOSCIENCES INC | $77,010,906 | -32.2% | 2,298,833 | -33.6% | 42.68% | +21.3% | |
PHVS | Sell | PHARVARIS N V | $18,353,922 | -29.0% | 2,278,575 | -0.8% | 10.17% | +27.0% |
Exit | CINCOR PHARMA INC | $0 | – | -383,390 | -100.0% | -1.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VERONA PHARMA PLC | 15 | Q2 2022 | 22.2% |
AKERO THERAPEUTICS INC | 14 | Q3 2022 | 65.3% |
ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 73.8% |
HARMONY BIOSCIENCES HLDGS IN | 13 | Q3 2023 | 21.1% |
APELLIS PHARMACEUTICALS INC | 11 | Q2 2021 | 62.0% |
PHARVARIS N V | 11 | Q3 2023 | 25.2% |
IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.3% |
ELEVATION ONCOLOGY INC | 10 | Q3 2023 | 4.2% |
VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 42.7% |
PRECISION BIOSCIENCES INC | 7 | Q3 2020 | 62.0% |
View venBio Partners LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
View venBio Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.